ProCE Banner Activity


Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies


Get up to date on individualizing therapy with BTK inhibitors for the management of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) by considering patient characteristics and the unique safety profile of available BTK inhibitors.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: October 11, 2023

Expiration: October 10, 2024



Matthew S. Davids

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Josie Montegaard

Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner


Supported by an educational grant from AstraZeneca.


Target Audience

The proposed educational program is intended for NPs and PAs.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patient and disease factors to consider in the choice of BTK inhibitors for CLL/SLL and MCL

  • Select guideline-recommended treatment strategies for the use of BTK inhibitors for patients with CLL/SLL and MCL

  • Apply strategies to manage toxicities associated with BTK inhibitors alone or in combination with other therapies


Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant/advisor/speaker: AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genmab, Genentech, Janssen, Lilly, MEI, Merck, Mingsight, Novartis, Nuvalent, Secura Bio, Surface Oncology, Takeda, TG Therapeutics.

Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Josie Montegaard, MSN, AGPCNP-BC: consultant/advisor/speaker: AbbVie, Beigene.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Susan J. Moench as noted below.

Susan J. Moench, PhD, PA-C: independent contractor: Gilead, Merck.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 11, 2023, through October 10, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit.

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 10, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.